6446 Stock Overview
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PharmaEssentia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$571.00 |
| 52 Week High | NT$735.00 |
| 52 Week Low | NT$281.00 |
| Beta | 0.51 |
| 11 Month Change | -10.50% |
| 3 Month Change | -16.89% |
| 1 Year Change | 58.39% |
| 33 Year Change | 192.82% |
| 5 Year Change | 412.11% |
| Change since IPO | 172.18% |
Recent News & Updates
Recent updates
We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings
Aug 20
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?
Apr 02Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term
Mar 18PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 06Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade
Mar 04PharmaEssentia (GTSM:6446) Is Using Debt Safely
Feb 10Shareholder Returns
| 6446 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -8.2% | -3.1% | -0.8% |
| 1Y | 58.4% | 2.0% | 29.0% |
Return vs Industry: 6446 exceeded the TW Biotechs industry which returned 2% over the past year.
Return vs Market: 6446 exceeded the TW Market which returned 29% over the past year.
Price Volatility
| 6446 volatility | |
|---|---|
| 6446 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6446 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6446's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
PharmaEssentia Corporation Fundamentals Summary
| 6446 fundamental statistics | |
|---|---|
| Market cap | NT$194.06b |
| Earnings (TTM) | NT$1.85b |
| Revenue (TTM) | NT$8.32b |
102.8x
P/E Ratio22.8x
P/S RatioIs 6446 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6446 income statement (TTM) | |
|---|---|
| Revenue | NT$8.32b |
| Cost of Revenue | NT$1.07b |
| Gross Profit | NT$7.25b |
| Other Expenses | NT$5.40b |
| Earnings | NT$1.85b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.55 |
| Gross Margin | 87.10% |
| Net Profit Margin | 22.19% |
| Debt/Equity Ratio | 0.3% |
How did 6446 perform over the long term?
See historical performance and comparison